MetLife Investment Management’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-21,677
| Closed | -$607K | – | 2948 |
|
|
2022
Q1 | $607K | Buy |
21,677
+7,706
| +55% | +$211K | ﹤0.01% | 1654 |
|
|
2021
Q4 | $382K | Hold |
13,971
| – | – | ﹤0.01% | 1652 |
|
|
2021
Q3 | $380K | Hold |
13,971
| – | – | ﹤0.01% | 1692 |
|
|
2021
Q2 | $239K | Hold |
13,971
| – | – | ﹤0.01% | 2040 |
|
|
2021
Q1 | $292K | Hold |
13,971
| – | – | ﹤0.01% | 1826 |
|
|
2020
Q4 | $320K | Hold |
13,971
| – | – | ﹤0.01% | 1726 |
|
|
2020
Q3 | $228K | Hold |
13,971
| – | – | ﹤0.01% | 1790 |
|
|
2020
Q2 | $189K | Hold |
13,971
| – | – | ﹤0.01% | 1944 |
|
|
2020
Q1 | $166K | Hold |
13,971
| – | – | ﹤0.01% | 1794 |
|
|
2019
Q4 | $348K | Hold |
13,971
| – | – | ﹤0.01% | 1652 |
|
|
2019
Q3 | $238K | Hold |
13,971
| – | – | ﹤0.01% | 1847 |
|
|
2019
Q2 | $318K | Hold |
13,971
| – | – | ﹤0.01% | 1757 |
|
|
2019
Q1 | $449K | Hold |
13,971
| – | – | ﹤0.01% | 1516 |
|
|
2018
Q4 | $394K | Hold |
13,971
| – | – | ﹤0.01% | 1521 |
|
|
2018
Q3 | $402K | Hold |
13,971
| – | – | ﹤0.01% | 1669 |
|
|
2018
Q2 | $523K | Buy |
13,971
+2,537
| +22% | +$99.6K | 0.01% | 1388 |
|
|
2018
Q1 | $449K | Hold |
11,434
| – | – | 0.01% | 1432 |
|
|
2017
Q4 | $370K | Buy |
+11,434
| New | +$343K | ﹤0.01% | 1581 |
|
MetLife Investment Management's XENT Position: Q2 2022 in Review
MetLife Investment Management sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 21,677 shares — an estimated $607K sold.
MetLife Investment Management first reported a position in XENT in Q4 2017 and held it in 18 quarters. The position peaked at $607K in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- MetLife Investment Management reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- MetLife Investment Management sold 21,677 Intersect ENT, Inc shares in Q2 2022, an estimated $607K.
- MetLife Investment Management first reported a position in Intersect ENT, Inc in Q4 2017 and held it in 18 quarters.
- MetLife Investment Management's Intersect ENT, Inc position peaked at $607K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.